Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eastwood Bio-Medical CanadaTSXV:EBM +1.02%25 Current Ratio is 0.05 as of Apr. 2026, which is 74% below its 10-year median of 0.19. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,408 Biotechnology companies, Eastwood Bio-Medical Canada ranks worse than 98.58% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Eastwood Bio-Medical Canada's current ratio for the quarter that ended in Apr. 2026 was 0.05.
Eastwood Bio-Medical Canada has a current ratio of 0.05. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Eastwood Bio-Medical Canada has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Eastwood Bio-Medical Canada's Current Ratio or its related term are showing as below:
TSXV:EBM'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.19 Max: 113.5
Current: 0.05
During the past 13 years, Eastwood Bio-Medical Canada's highest Current Ratio was 113.50. The lowest was 0.01. And the median was 0.19.
TSXV:EBM's Current Ratio is ranked worse than 98.58% of 1408
companies
in the Biotechnology industry
Industry Median: 3.88
vs TSXV:EBM: 0.05
Eastwood Bio-Medical Canada (TSXV:EBM) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Eastwood Bio-Medical Canada Current Ratio Related Terms
Eastwood Bio-Medical Canada Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:EBM vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's Current Ratio distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eastwood Bio-Medical Canada (TSXV:EBM) has a Current Ratio of 0.05 as of Apr. 2026. This is 74% below median its historical median of 0.19. Over the past decade, Eastwood Bio-Medical Canada's Current Ratio has ranged from 0.01 to 113.50. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #1388 out of 1408 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Eastwood Bio-Medical Canada's Current Ratio too high?
Eastwood Bio-Medical Canada's current Current Ratio of 0.05 is 74% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 113.50. The Biotechnology industry median Current Ratio is 3.88. Eastwood Bio-Medical Canada's value of 0.05 is 98.7% below this industry median. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #1388 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #1388 out of 1408 companies for Current Ratio. This places Eastwood Bio-Medical Canada in the lower half of its industry. The industry median Current Ratio is 3.88. Eastwood Bio-Medical Canada's value of 0.05 is 98.7% below this benchmark. Historically, Eastwood Bio-Medical Canada's own Current Ratio has ranged from 0.01 to 113.50 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 3.88, Eastwood Bio-Medical Canada has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eastwood Bio-Medical Canada's current Current Ratio of 0.05 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current Current Ratio is 0.05, which is 74% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current Current Ratio is 0.05, which is 74% below median its 10-year median of 0.19 and 98.7% below the Biotechnology industry median of 3.88. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current Current Ratio is 0.05 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
Current Ratio: 0.05 (74% below median its 10-year median of 0.19)
GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
Industry Position: 98.7% below the Biotechnology median (#1388 of 1408)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
